Ignite Creation Date:
2025-12-24 @ 2:52 PM
Ignite Modification Date:
2026-02-28 @ 12:29 PM
Study NCT ID:
NCT00486759
Status:
TERMINATED
Last Update Posted:
2017-07-25
First Post:
2007-06-14
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study of Bevacizumab (Avastin) in Combination With Rituximab (MabThera) and CHOP (Cyclophosphamide, Hydroxydaunorubicin [Doxorubicin], Oncovin [Vincristine], Prednisone) Chemotherapy in Patients With Diffuse Large B-cell Lymphoma
Sponsor:
Hoffmann-La Roche
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
BO20603
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None
Collaborators
Collaborators
| Name | Class | View |
|---|---|---|
| None | INDUSTRY | View |